Roche Says Avastin Study Misses Endpoint

Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.

The phase III trial comparing gemcitabine chemotherapy and Tarceva with or without Avastin as first-line treatment for advanced pancreatic cancer showed some evidence of clinical activity on secondary endpoints but the trial did not meet the primary endpoint of overall survival, Roche said in a statement.

Data from the AVITA trial are now being further analyzed to determine the extent of benefit of adding Avastin to the Tarceva/gemcitabine combination therapy, Roche said.

Avastin is made by U.S. biotech firm Genentech , which is majority owned by Swiss drugmaker Roche Holding.